Noticias

Noticias

  • Título: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • Fecha: 10-10-2016

  • MARLBOROUGH, Mass., Oct. 10, 2016 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that Professor Ian Meredith AM will join the company as executive vice president and global chief medical officer in January 2017. In his new position, Professor Meredith will lead clinical and medical affairs across Boston Scientific and will provide global leadership of the company's clinical trial strategy.

    Professor Meredith will succeed Executive Vice President and Global Chief Medical Officer Keith Dawkins, M.D., who has announced his intention to retire from the company in January 2017.

    'Ian is one of the world's leading cardiac device clinical investigators and he has been an advisor to Boston Scientific for many years,' said Mike Mahoney, chairman and chief executive officer, Boston Scientific. 'His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role. We are delighted that he will be joining our team.'

    'We thank Keith for his many contributions to Boston Scientific during the last nine years. His deep clinical, medical and strategic expertise and advocacy for the patient will have lasting influence within our company,' said Mahoney.

    Professor Meredith currently serves as professor of Medicine and Cardiology for Monash University, Director of MonashHeart and Monash Health and as executive director of the Monash Cardiovascular Research Centre in Melbourne, Australia. He brings to Boston Scientific more than 25 years of experience as a clinical and interventional cardiologist. He has performed more than 10,000 invasive cardiac and coronary procedures, published more than 300 manuscripts and has been chief or principal investigator on 30 major international multi-center trials, including first-in-man trials of new drug-eluting stents. Professor Meredith's work has focused on the development and clinical evaluation of devices for the treatment of coronary artery and structural heart disease, and he has been at the forefront of emerging percutaneous cardiac valve therapies. He was also the global principal investigator for the Boston Scientific Lotus™ Valve REPRISE research program.

    'Boston Scientific has demonstrated a commitment to delivering meaningful innovation and I look forward to joining the team to further develop the technology pipeline and deliver solutions for patients worldwide,' said Professor Meredith.

    Professor Meredith received undergraduate and doctorate degrees from Monash University in Melbourne, Australia. He trained in Melbourne and completed his Ph.D. at the Baker Institute before spending three years at the Brigham & Women's Hospital and Harvard Medical School in Boston.

    About Boston Scientific
    Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visitwww.bostonscientific.com and connect on Twitter and Facebook.

    Cautionary Statement Regarding Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like 'anticipate,' 'expect,' 'project,' 'believe,' 'plan,' 'estimate,' 'intend' and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and personnel moves. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.



  • Fuente: endovascular.es